These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36460479)

  • 1. Opportunities for Accelerating Drug Discovery and Development by Using Engineered Drug-Metabolizing Enzymes.
    Gillam EMJ; Kramlinger VM
    Drug Metab Dispos; 2023 Mar; 51(3):392-402. PubMed ID: 36460479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biocatalysis using Thermostable Cytochrome P450 Enzymes in Bacterial Membranes - Comparison of Metabolic Pathways with Human Liver Microsomes and Recombinant Human Enzymes.
    Jurva U; Sandinge AS; Baek JM; Avanthay M; Thomson RES; D'Cunha SA; Andersson S; Hayes MA; Gillam EMJ
    Drug Metab Dispos; 2024 Feb; 52(3):242-251. PubMed ID: 38176735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of enzymes of drug metabolism.
    Meyer UA
    J Pharmacokinet Biopharm; 1996 Oct; 24(5):449-59. PubMed ID: 9131484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NADPH-cytochrome P450 reductase expression and enzymatic activity in primary-like human hepatocytes and HepG2 cells for in vitro biotransformation studies.
    Schulz C; Kammerer S; Küpper JH
    Clin Hemorheol Microcirc; 2019; 73(1):249-260. PubMed ID: 31561354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
    Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
    Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolution of cytochrome P450 enzymes as biocatalysts in drug discovery and development.
    Gillam EM; Hayes MA
    Curr Top Med Chem; 2013; 13(18):2254-80. PubMed ID: 24047135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of engineered cytochromes P450 for accelerating drug discovery and development.
    Thomson RES; D'Cunha SA; Hayes MA; Gillam EMJ
    Adv Pharmacol; 2022; 95():195-252. PubMed ID: 35953156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes.
    Emoto C; Iwasaki K
    Xenobiotica; 2007 Sep; 37(9):986-99. PubMed ID: 17896325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions.
    von Moltke LL; Greenblatt DJ; Granda BW; Grassi JM; Schmider J; Harmatz JS; Shader RI
    Psychopharmacology (Berl); 1999 Jul; 145(1):113-22. PubMed ID: 10445380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design.
    Di L; Keefer C; Scott DO; Strelevitz TJ; Chang G; Bi YA; Lai Y; Duckworth J; Fenner K; Troutman MD; Obach RS
    Eur J Med Chem; 2012 Nov; 57():441-8. PubMed ID: 22840492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans.
    Marre F; Sanderink GJ; de Sousa G; Gaillard C; Martinet M; Rahmani R
    Cancer Res; 1996 Mar; 56(6):1296-302. PubMed ID: 8640817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.
    Gómez-Lechón MJ; Castell JV; Donato MT
    Chem Biol Interact; 2007 May; 168(1):30-50. PubMed ID: 17134688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Going Beyond Common Drug Metabolizing Enzymes: Case Studies of Biotransformation Involving Aldehyde Oxidase, γ-Glutamyl Transpeptidase, Cathepsin B, Flavin-Containing Monooxygenase, and ADP-Ribosyltransferase.
    Fan PW; Zhang D; Halladay JS; Driscoll JP; Khojasteh SC
    Drug Metab Dispos; 2016 Aug; 44(8):1253-61. PubMed ID: 27117704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
    Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
    Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism and pharmacokinetics characterization of metarrestin in multiple species.
    Padilha EC; Shah P; Wang AQ; Singleton MD; Hughes EA; Li D; Rice KA; Konrath KM; Patnaik S; Marugan J; Rudloff U; Xu X
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):805-816. PubMed ID: 32185484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro oxidative metabolism of cajaninstilbene Acid by human liver microsomes and hepatocytes: involvement of cytochrome p450 reaction phenotyping, inhibition, and induction studies.
    Hua X; Peng X; Tan S; Li C; Wang W; Luo M; Fu Y; Zu Y; Smyth H
    J Agric Food Chem; 2014 Oct; 62(43):10604-14. PubMed ID: 25272989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimation of Fraction Metabolized by Cytochrome P450 Enzymes Using Long-Term Cocultured Human Hepatocytes.
    Klammers F; Goetschi A; Ekiciler A; Walter I; Parrott N; Fowler S; Umehara K
    Drug Metab Dispos; 2022 May; 50(5):566-575. PubMed ID: 35246464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.
    Kalgutkar AS; Obach RS; Maurer TS
    Curr Drug Metab; 2007 Jun; 8(5):407-47. PubMed ID: 17584015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of drug metabolizing activities in pig hepatocytes for use in bioartificial liver devices: comparison with other hepatic cellular models.
    Donato MT; Castell JV; Gómez-Lechón MJ
    J Hepatol; 1999 Sep; 31(3):542-9. PubMed ID: 10488716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.